Novartis beats estimates, impresses in third quarter
This article was originally published in Scrip
Executive Summary
Novartis has posted a better-than-expected set of 3Q earnings: sales grew by 4% to $14.7bn while earnings per share (EPS) jumped by 10% to $1.37. Analysts had anticipated a strong quarter but consensus estimates put growth flat at $14.34bn with EPS of around $1.29, compared with the same period in 2013 (scripintelligence.com, 23 October 2014).
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.